At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AIMD AINOS Inc.
Closed Mourning Day 01-08 16:00:00 EST
0.5731
-0.0829
-12.64%
盘后0.5689
-0.0042-0.73%
19:53 EST
High0.6665
Low0.5200
Vol296.55K
Open0.6400
D1 Closing0.6560
Amplitude22.33%
Mkt Cap8.07M
Tradable Cap5.42M
Total Shares14.09M
T/O167.73K
T/O Rate3.13%
Tradable Shares9.46M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Ainos Files for Secondary Offering of 6.7 Million Shares; Shares Rise
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.